Home > Boards > US Listed > Biotechs > Ruthigen, Inc. (RTGN)

SANTA ROSA, Calif., July 17, 2014 /PRNewswire/ --

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
~S.B.A.~ Member Profile
 
Followed By 93
Posts 4,572
Boards Moderated 0
Alias Born 01/29/12
160x600 placeholder
~S.B.A.~   Tuesday, 08/05/14 09:23:18 PM
Re: onewhoknows2much post# 85
Post # of 107 
SANTA ROSA, Calif., July 17, 2014 /PRNewswire/ -- Ruthigen, Inc., (RTGN) today announced that it has treated the first human subjects with its leading drug candidate RUT58-60 in a 30 patient, 21-day skin irritation trial, which is expected to be completed in August 2014.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences